Deltex Medical Regulatory News (DEMG)

18 Sep 2006 10:06

Deltex Medical Group PLC18 September 2006 Deltex Medical Group plc CardioQTM and Freeman hospital trial results featured in presentations and discussion at the First European Society of Coloproctolgy (ESCP) Meeting (18) September 2006 Deltex Medical Group plc ('Deltex Medical' or the'Company'), the UK's leading haemodynamic monitoring company, today announcesthe presentation of results from the recently published trial at the Freemanhospital into the use of CardioQ at the inaugural meeting of the ESCP in Lisbon,Portugal, held on 13-16 September 2006. This presentation formed the centrepieceof Friday morning's presentations and discussion on oesophageal Dopplermonitoring (ODM) in surgery. More than 600 colorectal surgeons from the UK, Europe and the USA heard DrSophie Noblett, the trial's lead author, describe the outcome of this researchand its implications for improving outcomes and reducing length of hospital stayfor patients undergoing colorectal surgery. Dr Noblett also reviewed theexisting, large body of positive clinical data from research using the CardioQ,comprising six randomised, controlled clinical trials for the audience. It isthis evidence that makes Deltex Medical's CardioQ unique as the onlyintra-operative haemodynamic monitor proven in repeated randomised controlledtrials to reduce complications and length of hospital stay. Shortly after Dr Noblett's presentation, her colleague and fellow researcher, MrAlan Horgan, consultant colorectal surgeon at the Freeman hospital, chaired asymposium on so-called 'enhanced recovery programmes', a focus area for manycolorectal surgeons around the world. This symposium examined the importance ofsurgical approach, anaesthetic technique and nutritional management in helpingpatients recover more quickly and with fewer complications after their surgery. The use of oesophageal Doppler was considered by the presenters to be a valuablecomponent of such programmes. Mr Horgan explained to the audience that the useof the CardioQ was a key part of the enhanced recovery programme at the Freemanhospital and had played an important role in allowing the hospital to reduce itslength of hospital stay for patients undergoing colorectal surgery from twelveto four days. Deltex Medical's chief executive, Andy Hill, commented: "The response of delegates at this meeting to the presentations has beenextremely favourable and many of them came to request further information at ourexhibition stand at the meeting. We expect to be running educational sessions ina number of hospitals in the UK, Europe and the US in the coming months as adirect result of the high level of interest generated at this meeting". For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Nigel Chairman nigel.keen@deltexmedical.comAndy Hill, Chief Executive ah@deltexmedical.comEwan Phillips, Finance Director ep@deltexmedical.com Gavin Anderson & Company 020 7554 1400Deborah Walter dwalter@gavinanderson.co.ukMarie Cairney mcairney@gavinanderson.co.ukJodie Reilly jreilly@gavinanderson.co.uk Charles Stanley Securities 020 7149 6457Philip Davies philip.davies@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQ which have repeatedly:- • Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • Proved that the CardioQ works in a wide range of surgical procedures • Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange